A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer.
It comes as new trial data suggests Leqvio, also known as inclisiran and made by Novartis, helped patients meet their cholesterol goals faster than other therapies.
Patients also experienced less muscle pain, a side-effect of the cholesterol-lowering medication statins.
Cholesterol is a fatty substance made by the liver and found in some foods.
There are two types; good cholesterol, which removes excess cholesterol; and bad cholesterol, which can build up in the arteries and increase the risk of heart attacks and stroke.
